Mixed adenoneuroendocrine carcinoma of the distal bile duct: a case report

Takashi Maeda1*, Kyohei Yugawa1, Nao Kinjo1, Hiroto Kayashima1, Daisuke Imai1, Koto Kawata1, Shinichiro Ikeda1, Keitaro Edahiro1, Kazuki Takeishi2, Tomohiro Iguchi2, Noboru Harada2, Mizuki Ninomiya2, Shohei Yamaguchi1, Kozo Konishi1, Shinichi Tsutsui1 and Hiroyuki Matsuda1

Abstract

Background: Mixed adenoneuroendocrine carcinoma (MANEC) of the common bile duct (CBD) is very rare, with only 10 reported cases. Here, we report a case of MANEC of the distal bile duct (DBD) that was surgically resected under a diagnosis of cholangiocarcinoma (CCA).

Case presentation: A 60-year-old male had epigastric pain and was admitted to our hospital for the treatment of a suspected CBD stone. Upon admission, laboratory findings revealed elevated hepatobiliary enzymes including serum aspartate aminotransferase, serum alanine aminotransferase, serum glutamyltransferase, and serum alkaline phosphatase. Both carcinoembryonic antigen and carbohydrate antigen 19-9 were negative. Computed tomography (CT) showed dilation of the CBD. Endoscopic retrograde cholangiopancreatography (ERCP) showed circumferential stenosis and a 5-mm elevated lesion in the DBD. Brush cytology showed atypical ductal cells, indicating adenocarcinoma (AC) of the DBD. Under a diagnosis of CCA of the DBD, a subtotal stomach-preserving pancreaticoduodenectomy was performed. Neither peritoneal dissemination nor lymph node metastasis was found. Microscopically, the lesion was seen to be composed of predominantly well-differentiated tubular AC in the superficial layer of the tumor, admixed with neuroendocrine carcinoma (NEC) in the deeper portion, indicating a diagnosis of MANEC of the DBD. After immunohistochemical staining, NEC components were positive for synaptophysin and CD56 and were for SSTR2, SSTR5, and mammalian target of rapamycin (mTOR). Three months postsurgery, postoperative adjuvant chemotherapy with S-1 was started. More than 3 years postsurgery, he is alive without recurrence.

Conclusions: MANEC is highly malignant, progresses rapidly, and has a poor prognosis. Preoperative diagnosis is difficult; therefore, identifying NEC components by immunohistochemical staining using resected specimens is important.

Keywords: Neuroendocrine neoplasm, Mixed adenoneuroendocrine carcinoma, Immunohistochemistry
14.0 g/dl; platelet count, 28.9 × 10^4/μl; C-reactive protein, 0.35 mg/dl; total bilirubin, 2.0 mg/dl; direct bilirubin, 0.4 mg/dl; serum aspartate aminotransferase, 307 IU/l; serum alanine aminotransferase, 409 IU/l; serum glutamyltransferase, 932 IU/l; and serum alkaline phosphatase, 534 IU/l. Regarding tumor markers, carcinoembryonic antigen was 1.7 ng/ml (normal range < 5.0 ng/ml) and carbohydrate antigen 19-9 was 9.6 U/ml (normal range < 37.0 ng/ml). Viral markers for hepatitis, including hepatitis B surface antigen and hepatitis C viral antibody, were negative.

Abdominal contrast-enhanced computed tomography (CT) showed a slightly dilated CBD and a high-density spot in the DBD, suggesting a CBD stone (Fig. 1). Endoscopic ultrasonography demonstrated an elevated lesion on the DBD (Fig. 2). Permeation to the pancreatic parenchyma or to the outside of the bile duct wall was unclear. Endoscopic retrograde cholangiopancreatography (ERCP) revealed a circumferential stenosis 11.8 mm distal from the ampulla of Vater and a 5.1 × 6.5 mm irregularly shaped, elevated lesion on the DBD (Fig. 3). A double pig-tail catheter (7 Fr, 6 cm) was inserted in the bile duct. Brush cytology showed atypical ductal cells, indicating adenocarcinoma (AC) of the DBD.

Under a diagnosis of primary cholangiocarcinoma (CCA) of the DBD, a subtotal stomach-preserving pancreaticoduodenectomy was performed. Neither peritoneal dissemination nor lymph node metastases were found during the operation. Macroscopically, an irregularly shaped nodular tumor was found in the DBD (Fig. 4). Microscopically, the lesion was seen to be composed of predominantly well-differentiated tubular AC in the superficial layer of the tumor, admixed with neuroendocrine carcinoma (NEC) in the deeper portion (Fig. 5), indicating a diagnosis of MANEC of the DBD. While the AC component shows papillary growth toward the lumen of the bile duct, the NEC component had infiltrated into the muscle layer, with vascular and neural invasion. Atypical epithelium was found extensively in the superficial epithelium and accessory glands of the CBD, but...
no malignancies were found in the gallbladder, cholecystic duct, papilla of Vater, pancreas, or duodenum; based on this, the final pathological diagnosis was MANEC of the CBD, Pat Bi, fm, pPan0, pDu0, pHM0, pEM0, tubular, well-differentiated tubular AC>NEC, INF β, int, h0, v0, pm1. No lymph node metastases were found. After immunohistochemical staining, NEC components were diffusely positive for synaptophysin and CD56, and the MIB-1 index was 30% (Fig. 6). In both components, p16 was positive and p53 was negative. Additionally, the NEC component was strongly positive for SSTR2, SSTR5, and mammalian target of rapamycin (mTOR) (Fig. 7).

The postoperative course was good, there were no serious complications, and he was discharged 33 days post-operation. Three months postsurgery, postoperative adjuvant chemotherapy with S-1 (120 mg/body/day) was started. More than 3 years postsurgery, he is alive without recurrence.

**Discussion**

Neuroendocrine neoplasms (NENs) are composed a group of tumors exhibiting neuroendocrine phenotypes and are divided into three main categories according to the 2010 World Health Organization classification system: well-differentiated neuroendocrine tumors (NETs); grade 1 and 2, Ki-67 ≤ 20% and/or mitotic count ≤ 20 per 10 high-power fields, poorly differentiated NECs; and grade 3, Ki-67 > 20% and/or mitotic count > 20 per 10 high-power fields and MANECs [11]. Eighty percent of tumors arising in the extrahepatic biliary tract (EHBT) are well-differentiated AC; NENs are uncommon [12–21] and MANECs even more so. MANEC refers to a composite tumor characterized by coexisting glandular and neuroendocrine elements, with each accounting for > 30% of the lesion. Because of its histological complexity, the characteristics of MANEC remain poorly elucidated [9].

MANECs predominantly occur in the colon, appendix, and stomach where neuroendocrine cells are diffusely distributed [22, 23]. However, MANECs arising from the EHBT are extremely rare, with a total of 10 cases reported in the medical literature since the introduction of WHO category in 2010 (Table 1). Zhang et al. [9] reviewed the 38 cases of NEN in the EHBT, and MANECs constituted only 9 (23.7%) of the cases identified.

A high rate of misdiagnosis occurs with biliary NEN because its imaging results can appear similar to those of CCA. A well-vascularized, hypodense, and heterogeneously enhanced lesion is observed in CT scans. The common characteristics are lymph node enlargement and upstream bile duct dilation. In magnetic resonance images, biliary NENs mostly appear as nodular (45%) and intraductally growing (45%) shapes and less frequently as periductal infiltration (9%) [24]. In positron emission tomography, high glucose metabolism is usually found in NEN, especially in poorly differentiated NEC [25]. Because of the paucity of tissue obtained from ERCP brush cytology, MANEC is seldom diagnosed preoperatively. The AC component of MANEC is generally detected at the tumor surface, while the neuroendocrine component is found in the deep stroma, infiltrating the stromal and vascular tissues and lymph nodes [21]. Therefore, ERCP may fail to reach the neuroendocrine component, which is embedded in a deeper portion of the tumor [7].

Making an accurate preoperative diagnosis of biliary NEN is extremely difficult due to its indefinite clinical and imaging characteristics; as a result, most MANECs are diagnosed only after surgery.
of the bile duct are initially thought to be ACs or NETs [6, 7, 26]. A previous study examined 274 cases of surgically resected biliary tract cancer specimens and reported that 13 of 53 extrahepatic bile duct cancer cases contained neuroendocrine cells and 2 were newly diagnosed as MANEC [21]. Our patient was also first diagnosed with CCA by brush cytology, probably because the AC component was localized in the superficial layer and the NEC component was located in the deeper portion.

Therefore, to make a correct pathologic diagnosis of MANEC, a surgically resected specimen with immunohistochemical staining for neuroendocrine markers may be essential for the correct diagnosis [6–9]. Of the commonly used neuroendocrine markers, two of the most reliable are synaptophysin and chromogranin. Synaptophysin, with its small clear vesicles in tumor cells, and chromogranin, with its large neurosecretory granules, are usually stained diffusely in NEN [9]. CD56 (NCAM) is also used as a neuroendocrine marker [21]. In our case, NEC components were diffusely positive for synaptophysin and CD56 on immunohistochemical staining.

The prognosis of biliary MANEC is generally poor. The natural history of these tumors is still under debate with some reporting the NEC component showing more aggressive behavior, whereas others have concluded that, if the NEC component is well-differentiated, prognosis depends on the AC component [8]. However, the NEC component is said to have a greater effect on prognosis. Zhang et al. [9] reported significant variation by pathological type in the survival outcome of patients with NEN in the EHBT. The median overall survival for patients diagnosed with NET, NEC, and MANEC was 100, 7.7, and 16.6 months, respectively. Additionally, old age and tumor recurrence were found to negatively affect clinical outcomes. The Ki-67 staining index and mitotic count are crucial for tumor grading, as defined in the classification systems [11]. Harada et al. [21] reported that NEC components showed higher proliferative activity on Ki-67 immunostaining, compared to AC components, suggesting that neuroendocrine components, particularly NEC, in biliary MANEC could determine prognosis. In this case, the Ki-67 index of the NEC component was 30%, which was higher than that of the AC component.

The treatment algorithm for MANEC is not well established [7–9]. Surgery may be a mainstay for the treatment of MANEC, and adjunctive therapy with chemotherapy, radiotherapy, and somatostatin analogs can be considered according to the NEC type [7–9]. The chemotherapy regimen selection for MANEC remains a major clinical dilemma, since it

![Fig. 6](image6.png) On immunohistochemical staining, NEC components were diffusely positive for (a) synaptophysin and (b) CD56, and the MIB-1 index was 30% (c).

![Fig. 7](image7.png) NEC component was strongly positive for (a) SSTR2, (b) SSTR5, and (c) mTOR.
is complicated by a mixture of distinctive malignant histologies. It is reasonable to treat MANEC in accordance with the more aggressive component of the tumor. MANECs containing a well-differentiated NET component and AC component should be treated as ACs. MANECs containing a poorly differentiated NEC component should be treated as NECs. A NEN shown to possess the receptor for somatostatin (SSTR) is a good candidate for treatment with a somatostatin analog. In this case, SSTR2 and mTOR were positive in the NEC component upon immunohistochemical staining, indicating the use of somatostatin analogs as adjuvant therapy. Therefore, after tumor resection, the pathological differentiation and diagnosis of NENs is important for chemotherapy [21]. Adjuvant therapies have been seldom attempted in patients with biliary MANEC because clear, consensus-based evidence is lacking. However, adjuvant chemotherapy may be justified, as recurrent events were noted in 2/9 patients (22.2%) [9]. In this case, S-1 was administered 3 months postsurgery as adjuvant chemotherapy because the AC component was dominant in the tumor. Further studies are required to tailor chemotherapy strategies and to determine which component to target to obtain the best therapeutic benefits.

Conclusions
Herein, we presented the case of a 60-year-old male with MANEC of the DBD. Most MANEC cases, including this one, are initially diagnosed as CCA. Because MANEC may show more aggressive behavior and have a poor prognosis, it may be important to identify the NEC component using immunohistochemical staining with neuroendocrine markers for correct diagnosis and choice of treatment.

Table 1 Summary of reported cases of MANEC of the common bile duct

| Author [ref] | Age (yr) | Sex | Size (cm) | Preop. diagnosis | Pathology (AC/NEC) | IHC | Treatment | Prognosis |
|--------------|---------|-----|----------|------------------|-------------------|-----|-----------|-----------|
| Izumo W [1]  | 66      | M   | 1.0×0.8  | CCA mode/large   | CA, SP            | PD  | 30m, alive |
| Komo T [2]   | 82      | M   | 1.8      | CCA well/small   | CA, SP            | PD  | 7m, alive  |
| Masui T [3]  | 82      | M   | 2.5      | CCA well/small   | CA, SP, CD       | BDR | 6M, died  |
| Linder R [4] | 82      | M   | 1.9×1.2  | CCA poor/small   | CA, SP, CD       | PD  | 6m, alive  |
| Onishi I [5] | 74      | F   | 2.0      | IPNB clear/large | CA, SP, CD       | BDR | 5m, died  |
| Wysocki J [6]| 65      | M   | 3.6      | NA clear/large   | CA, SP, CD       | BDR | 11m, alive |
| Lee SW [7]   | 75      | M   | 2.0      | CCA mode/small   | CA, SP, CD       | BDR | 11m, alive |
| Akhilesh SP [8]| 76 | M   | 1.4×0.8  | ND mode/small    | SP, CD           | BDR | NA        |
| Zhang L [9]  | 64      | F   | 4.5×3.0  | CCA poor/small   | CA, SP, CD       | PD  | 12m, died |
| Present case | 60      | M   | 3.0      | CCA well/small   | SP, CD           | PD  | 36m, alive |

Abbreviations
MANEC: Mixed adenoneuroendocrine carcinoma; CBD: Common bile duct; DBD: Distal bile duct; CCA: Cholangiocarcinoma; AC: Adenocarcina; CT: Computed tomography; ERCP: Endoscopic retrograde cholangiopancreatography; NEC: Neuroendocrine carcinoma; NET: Neuroendocrine tumor; mTOR: Mammalian target of rapamycin; EHBT: Extrahepatic biliary tract.

Acknowledgements
The authors would like to thank Enago for the English language review.

Authors’ contributions
TM contributed to writing the manuscript. TM, HK, and DI performed the surgery and were responsible for the perioperative management of the patient. ST and HM supervised the study. All authors collected the data, discussed the content of the manuscript, and approved the final manuscript.

Funding
No funding was received in support of this work.

Availability of data and materials
All datasets supporting the conclusions of this article are included in this published article.

Ethics approval and consent to participate
The present study was conducted in accordance with the ethical standards of the Japan Surgical Society.

Consent for publication
Written informed consent was obtained from the patient for the publication of this case report and all accompanying images.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Surgery, Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital, 1-9-6 Senda-machi, Naka-ku, Hiroshima 730-8619, Japan.
2Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.

Received: 21 May 2020 Accepted: 22 June 2020
Published online: 06 July 2020

References
1. Izumo W, Higuchi R, Yazawa T, Uemura S, Matsunaga Y, Shihiara M, Furukawa T, Yamamoto M. A long-term recurrence-free survival of a patient with the mixed adeno-neuroendocrine bile duct carcinoma: a case report and review of the literature. Int J Surg Case Rep. 2017;39:43–50.
2. Komo T, Kohashi T, Nakashima A, Ohmori I, Hihara J, Mukaida H, Kaneko M, Hirabayashi N. Mixed adenoneuroendocrine carcinoma of the distal bile duct: a case report. Int J Surg Case Rep. 2017;39:203–7.
3. Masu T, Doi R, Kawaguchi Y, Iwamura Y, Ito T, Koizumi M, Uemoto S. Adenoneuroendocrine cell carcinoma of the extrahepatic bile duct: a case report and review of the literature. Clin J Gastroenterol. 2011;1:174–8.
4. Linder R, Dorfman T, Ben-Nishay O, Kakashvili V, Velodavsky E, Kluger Y. Mixed neuroendocrine tumor of the common bile duct. JOP. 2013 Jan 10;14(1):1–3.
5. Onishi I, Kitagawa H, Harada K, Maruzen S, Sakai S, Makino I, Hayashi H, Nakagawara H, Tajima H, Takamura H, et al. Intraductal papillary neoplasm of the bile duct accompanying biliary mixed adenoneuroendocrine carcinoma. World J Gastroenterol. 2013;19:3161–4.
6. Wysocki J, Aganwal R, Bratton L, Nguyen J, Weidenhaft MC, Shores N, Kimbell HZ. Mixed large cell neuroendocrine carcinoma and AC with spindle cell and clear cell features in the extrahepatic bile duct. Case Rep Pathol. 2014;2014:347949.
7. Lee SW, Lee IS, Cho YK, Park JM, Kim SW, Choi MG, Choi KY, Lee MA, Hong TH, You YK, Jung ES. A case of mixed adenoneuroendocrine carcinoma of the common bile duct: initially diagnosed as cholangiocarcinoma. Korean J Pathol. 2014 Dec;48(6):445–8.
8. Priyanka Akhilesh S, Kamal Sunder Y, Chandralekha T, Samir P, Prasad KW. Common hepatic duct mixed adenoneuroendocrine carcinoma masquerading as cholangiocarcinoma. Case Rep Gastrointest Med. 2016;2016:4827050.
9. Zhang L, Yang Z, Chen Q, Li M, Zhu Y, Wan D, Xie H, Zheng S. Mixed adenoneuroendocrine carcinoma in the extrahepatic biliary tract: a case report and literature review. Oncol Lett. 2019 Aug;18(2):1585–96.
10. Zhang HW, Kou K, Qi J, Xie EB, Wang M, Li Y, Lv GY, Wang GY. Mixed adenoneuroendocrine carcinoma of the extrahepatic bile duct: a case report. J Int Med Res. 2019 Jul;47(7):3421–6.
11. Bosman FT, Carneiro F, Hruban RH, Theise ND. Fourth Edition. IARC; Lyon: 2010. WHO classification of tumours of the digestive system.
12. Michalopoulos N, Papavramidis ST, Kanellos I, Papavramidis TS, Karayannopoulou G, Pliakos I. Neuroendocrine tumors of extrahepatic biliary tract. Pathol Oncol Res. 2014;20:765–75.
13. Sasatomi E, Nalesnik MA, Marsh JW. Neuroendocrine carcinoma of the extrahepatic bile duct: case report and literature review. World J Gastroenterol. 2013;19:4666–23.
14. Zheng Z, Chen C, Li B, Liu H, Zhou L, Zhang H, Zheng C, He X, Liu W, Hong T, Zhao Y. Biliary neuroendocrine neoplasms: clinical profiles, management, and analysis of prognostic factors. Front Oncol. 2019 Feb 5:9938.
15. Liu Z, Zhang DY, Lu Z, Zhang P, Sun WL, Ma X, Wu H, Wu Q, Zhou S. Neuroendocrine tumor of the common bile duct: a case report and review of the literature. Onco Targets Ther. 2018;11:2995–301.
16. Squalli S, Marchione R, Piccolominni M, Colombio D, Facci F, Bruno M, Bisciglia M. Well-differentiated neuroendocrine carcinoma (malignant carcinoid) of the extrahepatic biliary tract: report of two cases and literature review. APMIS. 2010;118:543–56.
17. Park SB, Moon SB, Ryu YJ, Hong J, Kim YH, Chae GB, Hong SK. Primary large cell neuroendocrine carcinoma in the common bile duct: first Asian case report. World J Gastroenterol. 2014;20:18048–52.
18. Hosoda K, Kobayashi A, Shinizu A, Kitagawa N, Ito T, Yamada A, Miyagawa S. Neuroendocrine tumor of the common bile duct. Surgery. 2016;160:525–6.
19. Oshio Y, Gen R, Hashimoto S, Oda T, Sato T, Ohkohchi N. Neuroendocrine carcinoma of the extrahepatic bile duct: a case report. World J Gastroenterol. 2016;22:6960–4.
20. Sano I, Kwatani M, Sugura R, Kato S, Kawakubo K, Ueno T, Nakaniishi Y, Mitsushashi T, Hirata H, Haba S, et al. Hepatobiliary and pancreatic: a rare case of a well-differentiated neuroendocrine tumor in the bile duct with spontaneous regression diagnosed by EUS-FNA. J Gastroenterol Hepatol. 2017;32:111.
21. Harada K, Sato Y, Ikeda H, Maylee H, Igarashi S, Okamura A, Masuda S, Nakamura Y. Clinicopathologic study of mixed adenoneuroendocrine carcinomas of hepatobiliary organs. Virchows Arch. 2012 Mar;460(3):281–9.
22. La Rosa S, Marando A, Sasca F, Capella C. Mixed adenoneuroendocrine carcinomas (MANECs) of the gastrointestinal tract: an update. Cancers (Basel). 2012 Jan 16(1):1–30.
23. La Rosa S, Marando A, Furlan D, Sahnane N, Capella C. Colorectal poorly differentiated neuroendocrine carcinomas and mixed adenoneuroendocrine carcinomas: insights into the diagnostic immunophenotype, assessment of methylation profile, and search for prognostic markers. Am J Surg Pathol. 2012;36:601–11.
24. Hong N, Kim HJ, Byun JH, Kim SY, Kim KW, Kim JH, Hong SM. Neuroendocrine neoplasms of the extrahepatic bile duct: radiologic and clinical characteristics. Abdom Imaging. 2015;40:181–91.
25. Murakami M, Katayama K, Kato S, Fujimoto D, Morikawa M, Koneki K, Hirono Y, Goi T. Large-cell neuroendocrine carcinoma of the common bile duct: a case report and a review of literature. Surg Case Rep. 2016;2:141.
26. Kim J, Lee WJ, Lee SH, Lee KB, Ryu JK, Kim YT, Kim SW, Yoon YB, Hwang JH, Han HS, Woo SM, Park SJ. Clinical features of 20 patients with curatively resected biliary neuroendocrine tumors. Dig Liver Dis. 2011 Dec;43(12):965–70.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Submit your manuscript to a SpringerOpen journal and benefit from:
► Convenient online submission
► Rigorous peer review
► Open access: articles freely available online
► High visibility within the field
► Retaining the copyright to your article

Submit your next manuscript at ► springeropen.com